55. McCraw,D.M.,Gallagher,J.R.&Harris,A.K.Characterizationofinfluenzavaccin
hemagglutinin complexes by cryo-electron microscopy and image analyse
revealsstructuralpolymorphisms.Clin.Vaccin.Immunol.23,483–495(2016).
56. Kost,T.A.&Condreay,J.P.Recombinantbaculovirusesasexpressionvectorsfo
insectandmammaliancells.Curr.Opin.Biotechnol.10,428–433(1999).
57. Webster,R.G.,Brown,L.E.&Jackson,D.C.Changesintheantigenicityofth
hemagglutininmoleculeofH3influenzavirusatacidicpH.Virology126,587–59
(1983).
58. Lee,P.S.&Wilson,I.A.Structuralcharacterizationofviralepitopesrecognizedb
broadly cross-reactive antibodies. Curr. Top. Microbiol. Immunol. 386, 323–34
(2015).
59. Turner,H.L.etal.Potentanti-influenzaH7humanmonoclonalantibodyinduce
separation of hemagglutinin receptor-binding head domains. PLoS Biol. 17
e3000139(2019).
60. Khurana,S.etal.Repeatvaccinationreducesantibodyaffinitymaturationacros
differentinfluenzavaccineplatformsinhumans.Nat.Commun.10,3338(2019)
61. Ekiert, D. C. et al. Antibody recognition of a highly conserved influenza viru
epitope.Science324,246–251(2009).
62. Kallewaard,N.L.etal.Structureandfunctionanalysisofanantibodyrecognizin
allinfluenzaAsubtypes.Cell166,596–608(2016).
63. Benhaim, M. A. etal. Structural monitoring of a transient intermediate in th
hemagglutininfusionmachineryoninfluenzavirions.Sci.Adv.6,eaaz8822(2020)
64. Portnoff,A.D.etal.Influenzahemagglutininnanoparticlevaccineelicitsbroadl
neutralizingantibodiesagainststructurallydistinctdomainsofH3N2HA.Vaccine
8,99(2020).
65. Richards,K.A.etal.RecombinantHA-basedvaccineoutperformssplitandsub
unit vaccines in elicitation of influenza-specific CD4 T cells and CD4 T cell
dependentantibodyresponsesinhumans.NPJVaccines5,77(2020).
66. Tay,T.etal.Investigationintoalternativetestingmethodologiesforcharacteriza
tionofinfluenzavirusvaccine.Hum.VaccinesImmunother.11,1673–1684(2015).
67. Gallagher, J. R. et al. Characterization of hemagglutinin antigens on influenz
virus and within vaccines using electron microscopy. Vaccines https://doi.org
10.3390/vaccines6020031(2018).
68. PublicHealthAgencyofCanada.Oculo-respiratorysyndromefollowinginfluenz
vaccination:reviewofpost-marketing surveillance throughfourinfluenza sea
sonsinCanada.Can.Commun.Dis.Rep.31,217–225(2005).
69. Choudhri,Y.&Walop,W.Influenzavaccine-associatedadverseevents:resultso
passive surveillance, Canada 2001-2002. Can. Commun. Dis. Rep. 28, 189–19
(2002).
70. Babiuk,S.etal.AggregatecontentinfluencestheTh1/Th2immuneresponset
influenzavaccine:evidencefromamousemodel.J.Med.Virol.72,138–142(2004)
71. Wei,C.J.etal.Cross-neutralizationof1918and2009influenzaviruses:roleo
glycansinviralevolutionandvaccinedesign.Sci.Transl.Med.2,24ra21(2010).
72. An, Y. et al. N-glycosylation of seasonal influenza vaccine hemagglutinins
implicationforpotencytestingandimmuneprocessing.JVirol.https://doi.org